Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy

Prostate Cancer and Prostatic Diseases volume 10, pages 119–126 (2007)Cite this article

Abstract

The management of high-risk prostate cancer following radical prostatectomy remains a treatment dilemma. Multimodality approaches incorporating surgery, radiation therapy and systemic agents offer the hope of improved cure rates; however, most randomized studies to date are either immature or negative. The systemic treatment options best studied is androgen deprivation, which has been shown to demonstrate a survival advantage in patients with lymph node-positive disease. Systemic chemotherapy has demonstrated a modest survival advantage in androgen-independent disease. Current studies are exploring its role in the adjuvant and neo-adjuvant setting. Lastly, recent randomized trials have demonstrated a biochemical advantage to adjuvant radiation therapy, but it remains to be seen if this will translate to an improvement is survival end points or if salvage radiation therapy would be just as effective. In this update article, we review the use of external beam radiation therapy and systemic agents in combination with surgery for high-risk prostate cancer patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics 2006. CA Cancer J Clin 2006; 56: 106–130.

    Article  Google Scholar 

  2. Tarone RE, Chu KC, Brawley OW . Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000; 11: 167–170.

    Article  CAS  Google Scholar 

  3. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417–424.

    Article  CAS  Google Scholar 

  4. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003; 57: 915–928.

    Article  Google Scholar 

  5. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC . Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555–565.

    Article  CAS  Google Scholar 

  6. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT . Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528–534.

    Article  Google Scholar 

  7. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ . Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004; 172: 910–914.

    Article  Google Scholar 

  8. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.

    Article  Google Scholar 

  9. Stephenson AJ, Kattan MW . Nomograms for prostate cancer. BJU Int 2006; 98: 39–46.

    Article  Google Scholar 

  10. Stephenson AJ, Scardino PT, Eastham JA, Bianco Jr FJ, Dotan ZA, DiBlasio CJ et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005–7012.

    Article  Google Scholar 

  11. Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL et al. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res 2003; 63: 4662–4670.

    CAS  Google Scholar 

  12. Grossfeld GD, Tigrani VS, Nudell D, Roach III M, Weinberg VK, Presti Jr JC et al. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol 2000; 164: 93–99 (discussion 100).

    Article  CAS  Google Scholar 

  13. Choo R, Hruby G, Hong J, Hong E, DeBoer G, Danjoux C et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys 2002; 52: 674–680.

    Article  Google Scholar 

  14. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF . Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American society for therapeutic radiology and oncology consensus panel. J Clin Oncol 1999; 17: 1155.

    Article  CAS  Google Scholar 

  15. Paulson DF, Moul JW, Robertson JE, Walther PJ . Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1990; 143: 1178–1182.

    Article  CAS  Google Scholar 

  16. Anscher MS, Robertson CN, Prosnitz R . Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. Int J Radiat Oncol Biol Phys 1995; 33: 37–43.

    Article  CAS  Google Scholar 

  17. Stein A, deKernion JB, Dorey F, Smith RB . Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles. Urology 1992; 39: 59–62.

    Article  CAS  Google Scholar 

  18. Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol 2000; 163: 1178–1182.

    Article  CAS  Google Scholar 

  19. Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, Zincke H . Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 1993; 42: 283–291.

    Article  CAS  Google Scholar 

  20. Catalona WJ, Smith DS . Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998; 160: 2428–2434.

    Article  CAS  Google Scholar 

  21. Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA . Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys 2005; 61: 714–724.

    Article  Google Scholar 

  22. Valicenti RK, Gomella LG, Ismail M, Strup SE, Mulholland SG, Dicker AP. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1999; 45: 53–58.

    Article  CAS  Google Scholar 

  23. Nilsson S, Norlen BJ, Widmark A . A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316–381.

    Article  Google Scholar 

  24. Eisbruch A, Perez CA, Roessler EH, Lockett MA . Adjuvant irradiation after prostatectomy for carcinoma of the prostate with positive surgical margins. Cancer 1994; 73: 384–388.

    Article  CAS  Google Scholar 

  25. Anscher MS . Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen. Int J Cancer 2001; 96: 91–93.

    Article  CAS  Google Scholar 

  26. Davis BJ, Pisansky TM, Leibovich BC . Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. Curr Opin Urol 2003; 13: 117–122.

    Article  Google Scholar 

  27. Kausik SJ, Blute ML, Sebo TJ, Leibovich BC, Bergstralh EJ, Slezak J et al. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer 2002; 95: 1215–1219.

    Article  Google Scholar 

  28. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572–578.

    Article  Google Scholar 

  29. Thompson Jr IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial 10.1001/jama.296.19.2329. JAMA 2006; 296: 2329–2335.

    Article  CAS  Google Scholar 

  30. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291: 1325–1332.

    Article  CAS  Google Scholar 

  31. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756–1764.

    Article  CAS  Google Scholar 

  32. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506–2513.

    Article  CAS  Google Scholar 

  33. Fowler Jr JE, Pandey P, Seaver LE, Feliz TP . Prostate specific antigen after gonadal androgen withdrawal deferred flutamide treatment. J Urol 1995; 154: 448–453.

    Article  Google Scholar 

  34. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15: 2928–2938.

    Article  CAS  Google Scholar 

  35. Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MH, Sartor AO et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58: 53–58.

    Article  CAS  Google Scholar 

  36. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–1520.

    Article  CAS  Google Scholar 

  37. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512.

    Article  CAS  Google Scholar 

  38. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–106.

    Article  CAS  Google Scholar 

  39. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW . 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821–827.

    Article  Google Scholar 

  40. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P et al. Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243–1252.

    Article  CAS  Google Scholar 

  41. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol 2003; 21: 3972–3978.

    Article  CAS  Google Scholar 

  42. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology 1997; 49: 56–64.

    Article  CAS  Google Scholar 

  43. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP . 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2–3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000; 38: 706–713.

    Article  CAS  Google Scholar 

  44. Klotz LH, Goldenberg SL, Jewett M, Barkin J, Chetner M, Fradet Y et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian urologic oncology group. Urology 1999; 53: 757–763.

    Article  CAS  Google Scholar 

  45. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood Jr DP et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002; 167: 112–116.

    Article  Google Scholar 

  46. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M et al. Hormonal treatment before radical prostatectomy: a 3-year followup. J Urol 1998; 159: 2013–2016 (discussion 2016–7).

    Article  CAS  Google Scholar 

  47. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791–794.

    Article  CAS  Google Scholar 

  48. Gleave ME, Goldenberg L, Chin JL, Warner J, Saad F, Klotz L et al. Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. AUA Annual Meeting 2003; Abstract 690.

  49. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001; 19: 44–53.

    Article  CAS  Google Scholar 

  50. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11: 5233–5240.

    Article  CAS  Google Scholar 

  51. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 1138–1142.

    Article  Google Scholar 

  52. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000; 18: 1050–1057.

    Article  CAS  Google Scholar 

  53. Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA . Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001; 57: 281–285.

    Article  CAS  Google Scholar 

  54. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the medical research council trial. Br J Urol 1997; 79: 235–246.

  55. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472–479.

    Article  CAS  Google Scholar 

  56. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K . Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865–1870.

    Article  CAS  Google Scholar 

  57. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43: 649–659.

    Article  CAS  Google Scholar 

  58. Rosenbaum E, Kibel A, Kattan MW, Sugar E, Garrett-Mayer E, Eisenberger M . Adjuvant weekly Docetaxel (D) for high risk prostate cancer (PC) patients (pts) following radical prostatectomy (RP). ASCO Prostate Cancer Symposium, 2006.

  59. Song DY, Thompson TL, Ramakrishnan V, Harrison R, Bhavsar N, Onaodowan O et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 2002; 60: 281–287.

    Article  Google Scholar 

  60. de la Taille A, Flam TA, Thiounn N, Pontvert D, Saighi D, Zerbib M et al. Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int 2002; 90: 887–892.

    Article  CAS  Google Scholar 

  61. Mayer R, Pummer K, Quehenberger F, Mayer E, Fink L, Hackl A . Postprostatectomy radiotherapy for high-risk prostate cancer. Urology 2002; 59: 732–739.

    Article  Google Scholar 

  62. Petrovich Z, Lieskovsky G, Langholz B, Jozsef G, Streeter Jr OE, Skinner DG . Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 600–609.

    Article  Google Scholar 

  63. Chawla AK, Thakral HK, Zietman AL, Shipley WU . Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. Urology 2002; 59: 726–731.

    Article  Google Scholar 

  64. Do LV, Do TM, Smith R, Parker RG . Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival. Am J Clin Oncol 2002; 25: 1–8.

    Article  Google Scholar 

  65. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001; 19: 1030–1039.

    Article  CAS  Google Scholar 

  66. Han M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC . Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. J Urol 2001; 165: 864–866.

    Article  CAS  Google Scholar 

  67. Catton C, Gospodarowicz M, Warde P, Panzarella T, Catton P, McLean M et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 2001; 59: 51–60.

    Article  CAS  Google Scholar 

  68. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000; 163: 845–850.

    Article  CAS  Google Scholar 

  69. Anscher MS, Clough R, Dodge R . Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys 2000; 48: 369–375.

    Article  CAS  Google Scholar 

  70. Peschel RE, Robnett TJ, Hesse D, King CR, Ennis RD, Schiff PB et al. PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. Int J Cancer 2000; 90: 29–36.

    Article  CAS  Google Scholar 

  71. Nudell DM, Grossfeld GD, Weinberg VK, Roach III M, Carroll PR . Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999; 54: 1049–1057.

    Article  CAS  Google Scholar 

  72. Corn BW, Winter K, Pilepich MV . Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85–31. Radiation Therapy Oncology Group. Urology 1999; 54: 495–502.

    Article  CAS  Google Scholar 

  73. Egawa S, Ohori M, Iwamura M, Kuwao S, Baba S . Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy. BJU Int 1999; 84: 815–820.

    Article  CAS  Google Scholar 

  74. Vicini FA, Ziaja EL, Kestin LL, Brabbins DS, Stromberg JS, Gonzalez JA et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 1999; 54: 111–117.

    Article  CAS  Google Scholar 

  75. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC . Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 159; 1998: 173–177 (discussion 177–178).

    Google Scholar 

  76. Garg MK, Tekyi-Mensah S, Bolton S, Velasco J, Pontes E, Wood Jr DP et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 1998; 51: 998–1002.

    Article  CAS  Google Scholar 

  77. Morris MM, Dallow KC, Zietman AL, Park J, Althausen A, Heney, NM et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38: 731–736.

    Article  CAS  Google Scholar 

  78. Crane CH, Rich TA, Read PW, Sanfilippo NJ, Gillenwater JY, Kelly MD . Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 1997; 39: 681–686.

    Article  CAS  Google Scholar 

  79. Zelefsky MJ, Aschkenasy E, Kelsen S, Leibel SA . Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1997; 39: 327–333.

    Article  CAS  Google Scholar 

  80. Medini E, Medini I, Reddy PK, Levitt SH . Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. Cancer 1996; 78: 1254–1259.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Urology, Washington University School of Medicine, St Louis, MO, USA

    A S Kibel

  2. Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    J B Nelson

Authors
  1. A S Kibel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J B Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A S Kibel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kibel, A., Nelson, J. Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy. Prostate Cancer Prostatic Dis 10, 119–126 (2007). https://doi.org/10.1038/sj.pcan.4500947

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500947

Keywords

Search

Advanced search

Quick links